Form 4: Boston Scientific Director Sells Shares Under 10b5-1 Plan

Boston Scientific Director Ellen M. Zane sold a total of 12,891 shares of common stock across two transactions in late October 2025, pursuant to a pre-established 10b5-1 trading plan.

Summary

• Ellen M. Zane, a Director of Boston Scientific Corp (BSX), reported two sales of common stock.
• On October 27, 2025, 9,990 shares were sold at a weighted average price of $101.1312 per share, with prices ranging from $100.57 to $101.405.
• On October 28, 2025, an additional 2,901 shares were sold at a weighted average price of $102.2402 per share, with prices ranging from $102.165 to $102.31.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on July 25, 2025.
• Following these transactions, Ellen M. Zane beneficially owns 24,134 shares of Boston Scientific common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sales were conducted under a pre-established 10b5-1 trading plan, which typically indicates personal financial planning rather than a reaction to company-specific news or a change in outlook.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence, though the pre-planned nature mitigates this concern.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe the reduction in director holdings, but the pre-planned nature of the sales under a 10b5-1 plan generally mitigates concerns about a lack of confidence in the company's future.

Key Dates

Recommendation

The reported transactions are routine sales by a director under a pre-established 10b5-1 trading plan, indicating personal financial planning rather than a change in company fundamentals or outlook. Therefore, it does not provide a strong signal to alter an investment position.

Keywords

Boston Scientific, BSX, Insider Trading, Form 4, Stock Sale, Ellen M. Zane, Director, 10b5-1 Plan, Medical Devices